Treatment options for alcoholic and non-alcoholic fatty liver disease: A review

被引:23
|
作者
Sukhpreet Singh [1 ]
Natalia A Osna [1 ,2 ]
Kusum K Kharbanda [1 ,2 ,3 ]
机构
[1] Research Service, Veterans Affairs Nebraska-Western Iowa Health Care System
[2] Department of Internal Medicine, Nebraska Medical Center
[3] Department of Biochemistry and Molecular Biology, Nebraska Medical Center
关键词
Alcoholic liver disease; Non-alcoholic fatty liver disease; Treatment options; Glucocorticoids; Liver transplantation;
D O I
暂无
中图分类号
R575 [肝及胆疾病];
学科分类号
1002 ; 100201 ;
摘要
Alcoholic liver disease(ALD)and non-alcoholic fatty liver disease(NAFLD)are serious health problems worldwide.These two diseases have similar pathological spectra,ranging from simple steatosis to hepatitis to cirrhosis and hepatocellular carcinoma.Although most people with excessive alcohol or calorie intake display abnormal fat accumulation in the liver(simple steatosis),a small percentage develops progressive liver disease.Despite extensive research on understanding the pathophysiology of both these diseases there are still no targeted therapies available.The treatment for ALD remains as it was 50 years ago:abstinence,nutritional support and corticosteroids(or pentoxifylline as an alternative if steroids are contraindicated).As for NAFLD,the treatment modality is mainly directed toward weight loss and co-morbidity management.Therefore,new pathophysiology directed therapies are urgently needed.However,the involvement of several inter-related pathways in the pathogenesis of these diseases suggests that a single therapeutic agent is unlikely to be an effective treatment strategy.Hence,a combination therapy towards multiple targets would eventually be required.In this review,we delineate the treatment options in ALD and NAFLD,including various new targeted therapies that are currently under investigation.We hope that soon we will be having an effective multi-therapeutic regimen for each disease.
引用
收藏
页码:6549 / 6570
页数:22
相关论文
共 50 条
  • [41] Non-alcoholic fatty liver disease
    Neuschwander-Tetri, Brent A.
    BMC MEDICINE, 2017, 15
  • [42] Non-alcoholic fatty liver disease
    Smith, Briohny W.
    Adams, Leon A.
    CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES, 2011, 48 (03) : 97 - 113
  • [43] Non-alcoholic fatty liver disease
    Carreras, MP
    Tortajada, GC
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2005, 97 (05) : 377 - 377
  • [44] Non-alcoholic fatty liver disease
    Sattar, Naveed
    Forrest, Ewan
    Preiss, David
    BMJ-BRITISH MEDICAL JOURNAL, 2014, 349
  • [45] Non-alcoholic fatty liver disease
    Li, Wenhao
    Alazawi, William
    CLINICAL MEDICINE, 2020, 20 (05) : 509 - 512
  • [46] Non-Alcoholic Fatty Liver Disease
    Engin, Atilla
    OBESITY AND LIPOTOXICITY, 2017, 960 : 443 - 467
  • [47] Non-alcoholic fatty liver disease
    Brent A. Neuschwander-Tetri
    BMC Medicine, 15
  • [48] Non-alcoholic fatty liver disease
    Alba, LM
    Lindor, K
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 17 (08) : 977 - 986
  • [49] Recent News on Statins for the Treatment of Non-Alcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis
    Athyros, Vasilios G.
    Katsiki, Niki
    Doumas, Michael
    CURRENT VASCULAR PHARMACOLOGY, 2018, 16 (02) : 104 - 106
  • [50] Parental non-alcoholic fatty liver disease increases risk of non-alcoholic fatty liver disease in offspring
    Long, Michelle T.
    Gurary, Ellen B.
    Massaro, Joseph M.
    Ma, Jiantao
    Hoffmann, Udo
    Chung, Raymond T.
    Benjamin, Emelia J.
    Loomba, Rohit
    LIVER INTERNATIONAL, 2019, 39 (04) : 740 - 747